Use of lipid-lowering agents in rheumatoid arthritis: A population-based cohort study

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1082-1088

  Veetil, Bharath Manu Akkara ^a   Myasoedova, Elena ^a   Matteson, Eric L ^a   Gabriel, Sherine E ^a   Crowson, Cynthia S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Lipid Lowering Therapy; Lipids; Rheumatoid Arthritis

Indexed keywords

ANTILIPEMIC AGENT; COLESEVELAM; COLESTYRAMINE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

LIPID-LOWERING THERAPY; LIPIDS; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84879940139     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121302     Document Type: Article

References (29)

1. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
3. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
4. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-8.
5. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: Effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006;8:R82.
6. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2005;52:402-11.
7. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.
8. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
9. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
10. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis-The Third National Health and Nutrition Examination Survey. J Rheumatol 2005;32:2311-6.
11. Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701-4.
12. van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: Serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8.
13. Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66:958-61.
14. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503-7.
15. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: Mechanisms and the impact of treatment. Semin Arthritis Rheum 2009;38:372-81.
16. van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: A meta-analysis. Semin Arthritis Rheum 2011;41:393-400.
17. Daien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: A systematic review with meta-analysis. Ann Rheum Dis 2012;71:862-8.
18. Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010; 69:683-8.
19. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: A nationwide cohort study. Ann Rheum Dis 2012;71:1496-501.
20. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
21. Melton LJ 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
22. Kremers HM, Myasoedova E, Crowson CS, Savova G, Gabriel SE, Matteson EL. The Rochester Epidemiology Project: Exploiting the capabilities for population-based research in rheumatic diseases. Rheumatology 2011;50:6-15.
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
24. Kremers HM, Bidaut-Russell M, Scott CG, Reinalda MS, Zinsmeister AR, Gabriel SE. Preventive medical services among patients with rheumatoid arthritis. J Rheumatol 2003;30:1940-7.
25. Curtis JR, Arora T, Narongroeknawin P, Taylor A, Bingham CO 3rd, Cush J, et al. The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther 2010;12:R144.
26. Soubrier M, Zerkak D, Dougados M. Indications for lowering LDL cholesterol in rheumatoid arthritis: An unrecognized problem. J Rheumatol 2006;33:1766-9.
27. Strandberg TE, Kovanen PT, Eklund KK. Is the "lipid paradox" in rheumatoid arthritis really a paradox? Arthritis Rheum 2011;63:3644-5.
28. Bartels CM, Everett C, McBride P, Smith M, Kind A, Mell M. Reply to letter to the editor entitled "Is the 'lipid paradox' in rheumatoid arthritis really a paradox?" by Strandberg et al. Arthritis Rheum 2011;63:3645-6.
29. Clearfield MB. Underidentification and undertreatment of dyslipidemia. J Am Osteopath Assoc 2003;103 Suppl 1:S5-8.